文献速递糖尿病

从其他基础胰岛素转换为德谷胰岛素可降低低血糖发生率:一项前瞻性研究

Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

这项多国、多中心、前瞻性、观察性、单臂研究纳入556例1型糖尿病和611例2型糖尿病成人患者,从其他基础胰岛素转换为德谷胰岛素并随访12个月。结果显示,两种糖尿病患者的总体、非严重、夜间低血糖发生率均显著降低,1型糖尿病严重低血糖也显著减少,同时血糖控制和治疗满意度改善。

要点

  • 1型糖尿病转换后总体低血糖发生率比为0.80(95%CI 0.74-0.88),严重低血糖为0.28(0.14-0.56)
  • 2型糖尿病转换后总体低血糖发生率比为0.46(95%CI 0.38-0.56),夜间低血糖为0.35(0.20-0.62)
  • 两种糖尿病患者的HbA1c和空腹血糖均显著下降,治疗满意度显著提高

核心结论

  • 在常规临床实践中,从其他基础胰岛素转换为德谷胰岛素与1型和2型糖尿病患者低血糖发生率显著降低相关。
  • 转换后血糖控制和治疗满意度均显著改善。

研究设计与样本

  • Results From Real-World Clinical Treatment With Tresiba®为多国、多中心、前瞻性、观察性、单臂研究。
  • 研究包括4周基线期(转换前基础胰岛素)和12个月随访期(德谷胰岛素)。
  • 纳入年龄≥18岁的1型糖尿病(n=556)和2型糖尿病(n=611)胰岛素治疗患者,计划起始德谷胰岛素。

主要发现

  • 1型糖尿病12个月随访/基线总体低血糖发生率比为0.80(95%CI 0.74-0.88),非严重为0.83(0.76-0.91),严重为0.28(0.14-0.56),夜间为0.61(0.50-0.73),均P<0.001。
  • 2型糖尿病低血糖发生率比总体为0.46(95%CI 0.38-0.56),非严重为0.53(0.44-0.64),夜间为0.35(0.20-0.62),均P<0.001;严重低血糖事件过少未分析。
  • 1型糖尿病12个月时HbA1c、空腹血糖和基础胰岛素剂量显著下降,体重增加,治疗满意度显著改善。
  • 2型糖尿病12个月时HbA1c和空腹血糖显著下降,体重和胰岛素剂量保持不变,治疗满意度显著改善。

临床怎么用

  • 对于接受基础胰岛素治疗的1型和2型糖尿病患者,转换为德谷胰岛素可考虑作为降低低血糖风险的策略。
  • 转换后应关注体重变化,尤其1型糖尿病患者体重可能增加。

局限性

  • 研究为单臂设计,无平行对照,结果可能受混杂因素影响。
  • 低血糖事件依赖患者日记记录,可能存在报告偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Observational studies of insulin degludec (degludec) with hypoglycemia events prospectively recorded are lacking. OBJECTIVE: To evaluate the safety and effectiveness of degludec in patients with type 1 diabetes (T1D) or type 2 diabetes (T2D) switching from other basal insulins in routine care. DESIGN: Results From Real-World Clinical Treatment With Tresiba® was a multinational, multicenter, prospective, observational, single-arm study comprising a 4-week baseline period (preswitch basal insulin) and 12-month follow-up (degludec). SETTING: Routine clinical practice. PATIENTS OR OTHER PARTICIPANTS: Insulin-treated patients (≥18 years) with T1D (n = 556) or T2D (n = 611) with treatment plans to initiate degludec. INTERVENTIONS: Switching to degludec from other basal insulins. MAIN OUTCOME MEASURE: Change from baseline in number of overall hypoglycemic events recorded in patient diaries. RESULTS: In T1D, the 12-month follow-up/baseline rate ratios (95% CI) of overall [0.80 (0.74 to 0.88)], nonsevere [0.83 (0.76 to 0.91)], severe [0.28 (0.14 to 0.56)], and nocturnal [0.61 (0.50 to 0.73)] hypoglycemia suggested significantly lower hypoglycemia rates with degludec (all Ps < 0.001). At 12 months, HbA1c, fasting plasma glucose (FPG), and basal insulin dosage decreased significantly. Body weight increased, and treatment satisfaction improved significantly. In T2D, the hypoglycemia rate ratios were overall [0.46 (0.38 to 0.56)], nonsevere [0.53 (0.44 to 0.64)], and nocturnal [0.35 (0.20 to 0.62)] (all Ps < 0.001; too few events for analysis of severe hypoglycemia). At 12 months, HbA1c and FPG decreased significantly. Body weight and insulin dosages remained unchanged, and treatment satisfaction was significantly improved. CONCLUSIONS: In a routine clinical care setting, switching to degludec from other basal insulins was associated with significantly lower rates of hypoglycemia, improved glycemic control, and treatment satisfaction in patients with T1D or T2D.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Fadini GP, Feher M, Hansen TK, et al. Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study. J Clin Endocrinol Metab. 2019. PMID: 31397845. doi:10.1210/jc.2019-01021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。